<DOC>
	<DOCNO>NCT00369070</DOCNO>
	<brief_summary>The purpose study estimate difference objective response rate paclitaxel/carboplatin plus AMG 706 arm ( Arm A B ) paclitaxel/carboplatin plus bevacizumab arm ( Arm C ) subject advanced non-squamous NSCLC .</brief_summary>
	<brief_title>A Phase 2 Trial AMG 706 Bevacizumab Combination With Chemo Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Men woman 18 year old histologically cytologically confirm advanced nonsquamous NSCLC ( unresectable stage IIIB pericardial pleural effusion stage IV/recurrent ) Measureable disease per RECIST criterion modify ECOG performance status 0 1 Ability take oral medication Competent give write informed consent Current prior history CNS metastases Any prior chemotherapy advance NSCLC History pulmonary hemorrhage gross hemoptysis within 6 month prior randomization Prior target therapy Known history allergy hypersensitivity paclitaxel carboplatin History arterial venous thrombosis within 52 week prior randomization History bleed diathesis nonpulmonary bleeding within 14 day prior randomization Peripheral neuropathy &gt; grade 1 per CTCAE Version 3.0 Myocardial infarction , cerebrovascular accident , grade 2 great peripheral vascular disease , transient ischemic attack , congestive heart failure , percutaneous transluminal coronary angioplasty/stent , ongoing arrythmias require medication unstable angina within 52 week prior randomization Any kind disorder compromise ability subject comply study procedure Uncontrolled hypertension define rest blood pressure &gt; 150/90 mm Hg . Antihypertensive medication allow hypertension stably control time randomization . Participation therapeutic clinical trial currently receive investigational treatment ( ) within 30 day prior randomization Pregnant breast feed woman Known HIV , hepatitis B surface antigen , hepatitis C positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>AMG 706</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Paclitaxel Carboplatin</keyword>
	<keyword>Randomized</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>